Saad Usmani is the Chief of the Myeloma Service at Memoria Sloan Kettering Cancer Center in New Yor, NY, where he leads a team of 13 investigators focused on multiple myeloma and plasma cell disorders. He has led the clinical development of several novel therapies, including anti-CD38 monoclonal antibodies, bispecific antibodies and CART cell therapies resulting in regulatory approvals in multiple myeloma. Prof. Usmani has authored/co-authored more than 300 peer-reviewed research manuscripts. Active in clinical and translational research, Dr. Usmani has particular interests in high-risk multiple myeloma.

Gösta Gahrton is professor emeritus in medicine at the Karolinska Institutet, and previous head of the Department of Medicine at the Karolinska University Hospital, Huddinge, Stockholm, Sweden and previous chairman of the Nobel committee at the Karolinska Institutet. He has been President of the EBMT and the World Marrow Donor Associations (WMDA)and performed one of the first allogeneic transplants in multiple myeloma, which led to many retrospective and prospective treatment studies of this disease in collaboration with EBMT.

Elena Zamagni is Associate Professor of Hematology at the Bologna University, Italy and head of the Myeloma Program. Her research interests include areas related to multiple myeloma, in particular on the role of high dose therapy with stem cell support, of prognostic factors, minimal residual disease and of imaging techniques. She has published over 200 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She is an active member of the board of the GIMEMA and European Myeloma Network (EMN) working party and she has cooperated in the Scientific secretary and as principal investigator in several national and international randomized trials in multiple myeloma.